| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 01/31/2002 | WO2002008255A2 Cell cycle proteins and mitosis-associated molecules |
| 01/31/2002 | WO2002008250A2 Ghrelin antagonists |
| 01/31/2002 | WO2002008242A1 Nucleic acids comprising regions of the rat peg-3 promoter and uses thereof |
| 01/31/2002 | WO2002008241A2 Prodrugs of phosphonate nucleotide analogues and methods for selecting and making same |
| 01/31/2002 | WO2002008231A2 Biologically active macrolides, compositions, and uses thereof |
| 01/31/2002 | WO2002008229A1 1-(4-oxo-3,5-dihydro-4h-pyridazino[4,5-b]indole-1-carbonyl(piperazine) derivatives, their preparation and therapeutic application |
| 01/31/2002 | WO2002008225A1 2-(1h-indol-3-yl)-2-oxo-acetic acid amides with antitumor activity |
| 01/31/2002 | WO2002008219A2 2-adamantylethylamines and their use in the treatment of conditions generally associated with abnormalities in glutamatergic transmission |
| 01/31/2002 | WO2002008217A2 COUMARIN DERIVATIVES USEFUL AS TNFα INHIBITORS |
| 01/31/2002 | WO2002008213A1 Colchinol derivatives as angiogenesis inhibitors |
| 01/31/2002 | WO2002008212A1 Novel form of (r)-n-[5-methyl-8-(4-methylpiperazin-1-yl)-1,2,3,4-tetrahydro-2-naphthyl]-4-morpholinobenzamide |
| 01/31/2002 | WO2002008200A2 Arylethene-sulfonamides, their preparation and their use as endothelin antagonists |
| 01/31/2002 | WO2002008194A1 Novel heteroaryl derivatives and the use thereof as pharmaceuticals |
| 01/31/2002 | WO2002008193A2 Therapeutic acridone and acridine compounds |
| 01/31/2002 | WO2002008192A1 Novel heteroaryl derivatives and the use thereof as pharmaceuticals |
| 01/31/2002 | WO2002008190A2 Novel heteroaryl derivatives and use thereof as anti-tumour agents |
| 01/31/2002 | WO2002008189A1 Compounds and inhibitors of phospholipases |
| 01/31/2002 | WO2002008188A1 N-substituted indoles useful in the treatment of diabetes |
| 01/31/2002 | WO2002008185A1 Pyrrolidine derivatives as metalloprotease inhibitors |
| 01/31/2002 | WO2002008174A1 Phenylethylamine derivatives and their use in the treatment of melanoma |
| 01/31/2002 | WO2002007823A2 Inhibition of mutagenic effects of carcinogens |
| 01/31/2002 | WO2002007777A1 USE OF THE INTERFERON RECEPTOR 2c POLYPEPTIDE CHAIN TO ENHANCE THE ANTI-GROWTH EFFECTS OF TYPE I INTERFERONS |
| 01/31/2002 | WO2002007771A1 Pharmaceutically active compound |
| 01/31/2002 | WO2002007770A2 Polymeric conjugates of antitumor agents |
| 01/31/2002 | WO2002007759A2 Clostridial toxin derivatives and methods for treating pain |
| 01/31/2002 | WO2002007744A1 Essential oil combination and therapeutic uses thereof |
| 01/31/2002 | WO2002007740A2 Snake toxin and use thereof as a pharmaceutical |
| 01/31/2002 | WO2002007739A2 Pharmaceutical preparation for the treatment and diagnosis of tumors and method for the preparation of the lipid free fraction of blood plasma |
| 01/31/2002 | WO2002007730A1 Alpha v integrin receptor antagonists |
| 01/31/2002 | WO2002007727A1 Use of pyridazino(4,5-)indole-1-acetamide derivatives for preparing medicines for treating pathologies related to the dysfunction of peripheral benzodiazepin receptors |
| 01/31/2002 | WO2002007722A2 Valproic acid and derivatives thereof as histone deacetylase inhibitors |
| 01/31/2002 | WO2002007720A1 Compounds having mif antagonist activity |
| 01/31/2002 | WO2002007719A1 Use of estramustine phosphate in the treatment of bone metastasis |
| 01/31/2002 | WO2002007712A2 Self-emulsifying drug delivery systems for extremely water-insoluble, lipophilic drugs |
| 01/31/2002 | WO2002007708A1 Lyophilized powder of lentinan and the process of preparation thereof |
| 01/31/2002 | WO2002007678A2 Mu-conopeptides |
| 01/31/2002 | WO2002007673A2 Calcilytic compounds |
| 01/31/2002 | WO2002007671A2 Intracellular delivery system for protein phosphatases and other polypeptides |
| 01/31/2002 | WO2002007670A2 Intracellular delivery system for protein phosphatases |
| 01/31/2002 | WO2002007514A2 Glycosylated vegf-b and method for increasing the amount of soluble vegf-b |
| 01/31/2002 | WO2001083562A3 Hybrid protein and vector encoding the same for inhibition of angiogenesis |
| 01/31/2002 | WO2001079158A3 Compounds for modulating cell proliferation |
| 01/31/2002 | WO2001074381A3 Calpain inhibitors in cancer treatment |
| 01/31/2002 | WO2001071015A3 Non-squamous epithelium-specific transcription |
| 01/31/2002 | WO2001070682A3 Carbocyclic side chain containing metalloprotease inhibitors |
| 01/31/2002 | WO2001070668A3 Amines substituted with a dihydronaphthalenyl, crhomenyl, or thiochromenyl group, an aryl or heteroaryl group and an alkyl group, having retinoid-like biological activity |
| 01/31/2002 | WO2001068146A3 Mixture comprising an inhibitor or suppressor of a gene and a molecule binding to an expression product of that gene |
| 01/31/2002 | WO2001064870A3 Mutated cyclin g1 protein |
| 01/31/2002 | WO2001062784A3 Use of breast cancer associated membrane proteins (bcmp) for treatment, prophylaxis and diagnosis of breast cancer |
| 01/31/2002 | WO2001062775A3 Novel antiarrhythmic peptides |
| 01/31/2002 | WO2001062341A3 Combination product for the treatment of obesity |
| 01/31/2002 | WO2001061017A3 Modified cytokines for use in cancer therapy |
| 01/31/2002 | WO2001060832A3 Pluraflavins and derivatives thereof, process for their preparation and use thereof |
| 01/31/2002 | WO2001048485A3 Selecting library members capable of binding to epitopes |
| 01/31/2002 | WO2001039788A3 Methods for targeting cells that express fibroblast growth receptor-3 or-2 |
| 01/31/2002 | WO2001038503A3 Novel human protein kinases and protein kinase-like enzymes |
| 01/31/2002 | WO2001036605A3 2786, a human aminopeptidase |
| 01/31/2002 | WO2001031343A3 Diagnosis and therapy of cancer using sgp28-related molecules |
| 01/31/2002 | WO2001008634A3 Polynucleotide encoding a human serine protease |
| 01/31/2002 | WO2000059941A9 Purposeful movement of human migratory cells away from an agent source |
| 01/31/2002 | US20020013485 Cytotoxic agents comprising taxanes and their therapeutic use |
| 01/31/2002 | US20020013484 Water solubility; prodrug containing polyether oligomer |
| 01/31/2002 | US20020013371 Therapy of acute myelogenous leukemia in a human by administering arsenic trioxide |
| 01/31/2002 | US20020013362 Used for administering paclitaxel to a patient with melanoma |
| 01/31/2002 | US20020013349 Administering drug which opens potassium channel for reducing pain |
| 01/31/2002 | US20020013347 Tri-aryl-substituted-ethane PDE4 inhibitors |
| 01/31/2002 | US20020013346 C7 ester substituted taxanes |
| 01/31/2002 | US20020013341 For therapy of acute infection, acute phase response, age related macular degeneration, alcoholism, anorexia, asthma, autoimmune disease, autoimmune hepatitis, Bechet's disease, cachexia, calcium pyrophosphate dihydrtate deposition |
| 01/31/2002 | US20020013334 HMG-CoA reductase inhibitors and method |
| 01/31/2002 | US20020013333 As inhibitors of matrix metalloproteinase, for therapy of diseases such as degenerative diseases and certain cancers |
| 01/31/2002 | US20020013328 For therapy of cancer or other proliferative diseases |
| 01/31/2002 | US20020013322 Novel compounds for enhancing chemotherapy |
| 01/31/2002 | US20020013319 For therapy of tumor or restenosis |
| 01/31/2002 | US20020013306 Terpyridine-platinum(ii) complexes |
| 01/31/2002 | US20020013299 For enhancing the chemotherapeutic treatment of tumor cells in a mammal with an antineoplastic alkylating agent, which causes cytotoxic lesions at the O6-position of guanine; O6-alkylguanine-DNA alkyltransferase (AGT) inactivator |
| 01/31/2002 | US20020013297 Halogenated triphenylethylene derivatives as selective estrogen receptor modulators |
| 01/31/2002 | US20020013287 Nucleosides, nucleoside analogs, abasic nucleosides, or heterocyclic derivatives linked by a phophodiester, a phosphorothioate or phosphonate group; sustained release; anticarcinogenic agents, viricides and microbiocides |
| 01/31/2002 | US20020013285 Nucleosome-based anti-tumor compositions |
| 01/31/2002 | US20020013278 Using an interleukin-1 beta converting enzyme inhibitor pro-drug to treat apoptosis-, interferon-gamma inducing factor or interferon-gamma inducing diseases; antiinflammatory and -proliferative agents; autoimmune/degenerative disesesdiseases |
| 01/31/2002 | US20020013274 Administering a covalently reactive antigen analog (CRAA) having an an epitope recognized irreversibly bound by catalytic antibody; autoimmune disease; a lymphoproliferative disorder; anticarcinogenic, -tumor, -inflammatory agents |
| 01/31/2002 | US20020013262 Method of inhibiting metastatic dissemination using desmopressin |
| 01/31/2002 | US20020013259 Therapeutic and diagnostic methods for ulcerative colitis and associated disorders |
| 01/31/2002 | US20020012992 Production of adenine nucleotide translocator (ANT), novel ANT ligands and screening assays therefor |
| 01/31/2002 | US20020012962 Nucleotide sequences coding fusion protein for use in the treatment of osteoporosis, cancers, and cachexia |
| 01/31/2002 | US20020012954 Compositions and methods for demonstrating secretory immune system regulation of steroid hormone responsive cancer cell growth |
| 01/31/2002 | US20020012931 High specificity marker detection |
| 01/31/2002 | US20020012906 Method for kidney disease treatment by drug intervention |
| 01/31/2002 | US20020012715 Protecting cell from damage caused by free radicals by administering lipophilic antioxidant comprising vitamin E, beta carotene, extract of Lycopersicum esculentum, hydrophilic antioxidant comprising vitamin c, extract of vitis vinifera |
| 01/31/2002 | US20020012708 For preparation of medicaments for treatment of organ and tissue damages caused by radiation, infections, and chemically, especially of O-MALT system of small intestine, bone marrow, spleen, lymph nodes, liver |
| 01/31/2002 | US20020012703 Treatment of oncologic tumors with an injectable formulation of a golgi apparatus disturbing agent |
| 01/31/2002 | US20020012696 In gene therapy and in in vitro and in vivo transfection |
| 01/31/2002 | US20020012665 Combined use of anti-cytokine antibodies or antagonists and anti-CD20 for treatment of B cell lymphoma |
| 01/31/2002 | US20020012663 Inhibiting the growth of refractory tumors that are stimulated by a ligand of epidermal growth factor receptor (EGFR) in human patients, comprising treating the human patients with an effective amount of an EGFR/HER1 antagonist |
| 01/31/2002 | DE10035144A1 Cyclische Aminosäurederivate Cyclic amino acid derivatives |
| 01/31/2002 | CA2725819A1 Prodrugs of phosphonate nucleotide analogues and methods for selecting and making same |
| 01/31/2002 | CA2418204A1 Novel peptides as ns3-serine protease inhibitors of hepatitis c virus |
| 01/31/2002 | CA2417508A1 Glycosylated vegf-b and method for increasing the amount of soluble vegf-b |
| 01/31/2002 | CA2417189A1 2-(1h-indol-3-yl)-2-oxo-acetic acid amides with antitumor activity |
| 01/31/2002 | CA2417185A1 Multivalent target binding protein |
| 01/31/2002 | CA2417127A1 Compounds and inhibitors of phospholipases |